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Abstract 
Drug-induced liver injury (DILI) is an important liver disease in China, owing to the country’s huge population and the 
availability of a multitude of drugs. Consequently, DILI is becoming an increasingly serious health problem. However, 
there is not enough relevant epidemiological data, and the clinical features of these patients are not clear. We con-
ducted this study to report the causes and clinical features of DILI in hospitalized patients, and identify the mortality 
and predictive factors. We retrospectively collected and analyzed the data of all hospitalized patients whose discharge 
diagnosis was DILI at the Second Xiangya Hospital between January 2011 and December 2014. The data analyses 
were performed using SAS version 9.2. Among the 469 patients who were diagnosed with DILI at discharge, 361 met 
the criteria for DILI on re-evaluation. The crude annual incidence rate of DILI was 92.95 cases per 100,000 patients. 
Chinese herbal medicine was identified as the primary cause of DILI in 36.01 % of the patients. The overall mortality 
was 8.59 %. Alcohol consumption, use of antituberculosis drugs, serum total bilirubin, direct bilirubin, total protein, 
albumin, thrombinogen time, international normalized ratio, and the model for end-stage liver disease (MELD) score 
were significantly correlated with DILI-associated mortality. Among them, the MELD score and albumin were found to 
be independent predictors of outcome in patients with DILI. Chinese herbal medicine was the primary cause of DILI 
in the identified patients. The MELD score and albumin were independent predictors of outcome in patients with DILI.
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Background
Drug-induced liver injury (DILI) is a serious condition 
that is characterized by varying degrees of liver injury. 
A variety of drugs can lead to various types of acute and 
chronic liver injury, and even severe or acute liver fail-
ure. In recent years, DILI has become one of the major 
liver diseases in many countries, even in the West; it is 
the leading cause of acute liver failure, with a survival 
rate of only 20 % in the absence of liver transplantation 
(Ostapowicz et al. 2002; Lee 2003). Statistical data from 
Iceland has shown that the crude annual incidence rate of 
DILI was 19.1 cases per 100,000 inhabitants: 75 % of the 
DILI cases were caused by a single prescription medica-
tion, 16  % by dietary supplements, and 9  % by multiple 
agents (Björnsson et  al. 2013). In Asia, herbal remedies 
are widely used and accepted as safe and effective medi-
cation, but they are often associated with high incidences 
of DILI. Data from Korea and Singapore show that herbs 
are the primary cause of DILI (Suk et al. 2012; Wai 2006). 
In China, because of the huge population and multitude 
of drugs available, especially, the vast number of Chinese 
herbal medicines, DILI is becoming an increasingly seri-
ous health problem. Although, a systematic analysis of 
the Chinese literature showed that tuberculostatics and 
complementary and alternative medicines are the most 
common etiologies of DILI in China (Zhou et al. 2013), 
but the relevant clinical features and outcomes of DILI 
are not mentioned. To further clarify the causes, clinical 
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features, and outcomes of DILI in hospitalized patients; 
we conducted this study by retrospectively collecting the 




We performed a retrospective study and collected data 
from all the hospitalized patients whose diagnosis at dis-
charge was DILI at the Second Xiangya Hospital (Hunan, 
China), who were hospitalized between January 1, 2011 
and December 31, 2014. Informed consent was waived 
due to the retrospective nature of the study. Patients 
were included if their diagnosis at discharge was “DILI,” 
“drug-induced hepatitis,” “drug-induced liver disease,” 
“drug-induced liver failure,” or other diagnostic termi-
nology that suggested some form of DILI. Patients were 
excluded (1) if their clinical information was incomplete, 
and therefore the diagnosis of DILI could not be con-
firmed, and (2) if DILI was ruled out after a re-evaluation.
The following data were collected: (1) general infor-
mation (gender, age, occupation, nationality, height, 
weight, etc.); (2) diagnosis at admission and discharge, 
disease history (including history of allergies), and drink-
ing history; (3) information about the drug suspected to 
have caused the liver injury; (4) symptoms and signs; (5) 
results of biochemical examinations, including alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), serum total bilirubin (TBIL), direct bilirubin 
(DBIL), albumin (ALB), globulin (GLO), thrombinogen 
time (PT), international normalized ratio (INR), alka-
line phosphatase (ALP), and creatinine (Cr), and routine 
blood examination results the first time DILI was diag-
nosed and at later examinations; (7) results of laboratory 
tests for other liver diseases (including HAV, HBV, HCV, 
HDV, HEV, EBV, CMV, and herpes virus infection, Wil-
son’s disease, autoimmune hepatitis, etc.); (8) imaging 
and endoscopic results; (9) results of liver histological 
examination; (10) severity and prognosis of DILI.
Diagnosis and evaluation of DILI
After the data were collected, we re-diagnosed all the 
patients according to the ACG clinical guidelines for the 
diagnosis and management of idiosyncratic DILI (Cha-
lasani et  al. 2014). Briefly, the R value was calculated 
(R value  =  Serum [ALT/ALT upper limits of normal 
(ULN)] ÷ [ALP/ALP ULN]), and Roussel Uclaf Causality 
Assessment Method (RUCAM) was performed. Patients 
with RUCAM scores less than six were excluded, and 
those with RUCAM scores greater than or equal to six 
were retained for further analysis. The type of DILI was 
determined according to the R value: it was hepatocellu-
lar if the R value was >5.0, cholestatic if the R value was 
<2.0, and mixed if the R value was in the range of 2.0–5.0 
(Chalasani et  al. 2014). Acute liver failure is defined as 
evidence of coagulation abnormality, usually an INR >1.5, 
and any degree of mental alteration (encephalopathy) in a 
patient without pre-existing cirrhosis and with an illness 
of less than 26 weeks’ duration (Polson 2005). The MELD 
score was calculated using the following formula (Said 
et al. 2004): 3.78 (Ln serum bilirubin [mg/dl]) + 11.2 (Ln 
INR) + 9.57 (Ln serum creatinine [mg/dl]) + 6.43. Hy’s 
law cases have been defined as drug-induced liver injury 
resulting in increased alanine aminotransferase (ALT) 
levels greater than three times ULN and TBIL levels 
greater than two times ULN after excluding other poten-
tial causes. To exclude cholestatic or mixed cases, the 
guidance for clinical trials states that for a Hy’s law case 
the liver injury should not have a significant ALP increase 
reflecting a cholestatic component (Temple 2006). Cases 
in which the ALT and TBIL corresponded to these values 
were classified as Hy’s cases.
Statistical analyses
Categorical variables were expressed as frequencies and 
percentages. Continuous variables were presented as 
median (range). Variables were analyzed using univariate 
and multivariate logistic regression analysis for dichoto-
mous outcomes. Odds ratios (ORs) and 95 % confidence 
intervals (CIs) were calculated from the confidence and 
standard errors of the model. Statistical significance was 
defined as a two-sided p value less than 0.05. The data 
analyses were performed using SAS version 9.2 (SAS 
Institute Inc., Cary, NC, USA).
Results
Incidence rate of DILI
The total number of 4-year hospitalized patients was 
388,365, and 469 (120.76/100,000) of them were diag-
nosed with DILI. Based on the RUCAM causality assess-
ment, 361 patients met the criteria for DILI, so the 
remaining 108 patients were excluded. The crude annual 
incidence rate of DILI in the hospitalized patients was 
92.95 cases per 100,000 patients. According to the age 
distribution of all the DILI patients (range, 1–90 years), 
the DILI incidence in age group 0–10, 11–20, 21–30, 
31–40, 41–50, 51–60,61–70,71–80 and 81–90 was 1.11, 
2.49, 12.37, 14.96, 25.49, 20.22,14.13,7.75 and 1.39  %, 
respectively. The age group with the highest incidence 
rate (25.49 %) was found to be 41–50 years and the sec-
ond highest incidence rate (20.22  %) was found to be 
51–60 years.
Baseline characteristics
Table 1 represents the demographic data, clinical features 
and laboratory findings of the patients the first time they 
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were diagnosed with DILI. Of the 316 patients, 195 were 
male and 110 were female, and their median age was 
49 years (range, 37–59). Most of the patients had hepa-
tocellular DILI (63.16  %), while 13.85  % had cholestatic 
DILI and 13.30  % had mixed-type DILI. The remaining 
patients (9.70 %) were not examined for ALP when they 
were diagnosed with DILI the first time, so the R value 
could not be calculated. Further, 32 (8.86  %) patients 
were HBsAg positive and 24 (6.65  %) were positive for 
the autoimmune hepatitis antibody; all the patients were 
negative for HCV, HAV, HEV, HDV and other hepato-
tropic viruses. Alcoholic liver disease was diagnosed in 
22 (6.09  %) patients, and NAFLD was diagnosed in 13 
(3.60  %) patients. Wilson’s diseases and other liver dis-
eases were not diagnosed in any of the patients. The total 
number of patients with pre-existing liver disease was 91 
(25.21 %), pre-existing decompensated liver diseases were 
not found in these patients.
Main clinical manifestations
The digestive symptoms, including nausea, anorexia, 
vomiting and abdominal distension, were observed in 
most patients (59.28  %). Jaundice was also one of the 
main clinical symptoms (52.63  %). Itching occurred 
in 13.30 % of the patients, fever in 15.51 %, and rash in 
8.31  %. Severe liver damage symptoms including hem-
orrhage tendency and hepatic encephalopathy occurred 
in 3.05 % of the patients. In 21.61 % of the patients, the 
results of liver biochemical examination were abnormal, 
but there were no symptoms.
Causative drugs
The number of DILI cases associated with each type 
of drug is shown in Table  2. We found Chinese herbal 
drugs to be the leading cause of DILI (36.01 %). Further, 
antithyroid and antituberculosis drugs accounted for 
more than 14 % of the DILI cases. As shown in Table 3, 
the most commonly implicated Chinese herbal medi-
cine were radix polygoni multiflori, panax pseudo-gin-
seng, Tripterygium wilfordii, saffron, shenbao mixture, 
and decoction of herbal medicine ingredients; the major 
implicated antithyroid were propylthiouracil and methi-
mazole; rifampicin, isoniazid and pyrazinamide were the 
major implicated antituberculosis. Antituberculosis and 
chemotherapy drugs were often involved in a combina-
tion at least two same class drugs.
Severity and prognosis of DILI
Among the 361 patients, 91.41 % survived. Among the 
31 (8.59  %) patients who died, 22 (70.97  %) died as a 
result of severe liver disease, 9 (29.03  %) as a result of 
Table 1 Baseline characteristics of the 361 patients
HBV Hepatitis B virus, NAFLD non-alcoholic fatty liver disease, ALT alanine 
transaminase, AST aspartate transaminase, ALP alkaline phosphatase, TBIL 
total bilirubin, DBIL bilirubin direct, PT prothrombin time, INR international 
normalized ratio, TP total protein, ALB albumin, Cr Creatinine, MELD model for 
end-stage liver disease
a  OR (95 % CI)
b  n (%)
Characteristics Total (N = 361)
Age (y) 49 (37, 59)a
Gender (M/F), n (%) 195 (54 %)/166 (46 %)b
Alcohol consumption, n (%) 33 (9.14 %)b
Pre-existing liver disease, n (%) 91 (25.21 %)b
HBV, n (%) 32 (8.86 %)b
Autoimmune antibodies, n (%) 24 (6.65 %)b
Alcoholic liver disease, n (%) 22 (6.09 %)b
NAFLD, n (%) 13 (3.60 %)b
Days from drug use to symptom appearance 30 (9, 60)a
Days from drug discontinuation to symptom
 Disappearance 20 (12, 30)a
 ALT (U/L) 225.7 (89.7, 541.3)a
 AST (U/L) 125.8 (57.1, 325.1)a
 ALP (U/L) 135.1 (81.7, 203.9)a
 TBIL (μmol/L) 53 (14.5, 237.1)a
 DBIL (μmol/L) 38.1 (6.7, 182.9)a
 PT (s) 13.3 (12, 16.6)a
 INR 1 (1, 1.4)a
 TP (g/L) 53 (14.5, 237.1)a
 ALB (g/L) 33.4 (29.5, 36.8)a
 Cr (μmol/L) 56.1 (45.8, 69)a
 MELD 6.9 (0.1, 13.3)a
Type of DILI
 Hepatocellular, n (%) 228 (63.16 %)b
 Cholestatic, n (%) 50 (13.85 %)b
 Mixed, n (%) 48 (13.30 %)b
 NA, n (%) 35 (9.70 %)b
Table 2 Causative drugs
Others include heroin, edaravone, omeprazole, thyroxine and amlodipine 
besylate, each of which was associated with less than four cases of DILI
Drug Cases (n) Percentage (%)




Chemotherapy drugs 22 6.09
Immunosuppressants 22 6.09
Antipyretics and analgesics 13 3.6
Psychotropic drugs 11 3.05
Antidiabetics 9 2.49
Lipid-lowering drugs 8 2.22
Others 17 4.71
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primary diseases, and 10 (32.26  %) died from anti-
TB drugs hepatoxity. According to Hy’s criteria, 71 
(19.67  %) patients were classified under Hy’s patients: 
9 (12.68  %) of these patients died from liver failure 
(Table 4).
Logistic regression analysis
Univariate logistic regression analysis showed that alco-
hol consumption, use of antituberculosis drugs, serum 
TBIL, DBIL, total protein, ALB, PT, INR and the MELD 
score were significantly associated mortality (p  <  0.05) 
Table 3 Specific drug of causing DILI
Category Specific drug Cases (n) Percentage (%)
Chinese herbal medicine Herbal medicine ingredients 91 70.00
Radix polygoni multiflori 15 11.54
Panax pseudo-ginseng 10 7.69
Tripterygium wilfordii 6 4.62
Saffron 4 3.08
And shenbao mixture 4 3.08
Antithyroid Propylthiouracil 26 50
Methimazole 26 50
Antituberculosis Isoniazid + rifampicin + pyrazinamide 29 56.86
Isoniazid + rifampicin 17 33.33
Rifampicin 4 7.85
Isoniazid + pyrazinamide 1 1.96


















Antipyretics and analgesics Acetyl aminophenol 9 69.23
Meloxicam 2 15.38
Celecoxib 2 15.38
Psychotropic drugs Clozapine 3 27.27
Olanzapine 2 18.18
Carbamazepine 2 18.18
Dilantin sodium 2 18.18
Lithium carbonate 2 18.18
Antidiabetics Metformin 5 55.56
Gliclazide 2 22.22
Acarbose 2 22.22
Lipid-lowering drugs Statins 8 100
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(Table  5). The correlation coefficient values indicated 
that alcohol consumption, the use of antituberculo-
sis drugs, serum TBIL, DBIL, PT, INR and the MELD 
score were positively correlated with mortality, while the 
total protein and ALB were negatively correlated with 
mortality. The hazard ratio showed that among all the 
predictors, use of antituberculosis drugs was the most 
hazardous factor correlated with the mortality rate, fol-
lowed by alcohol consumption and then INR (Fig.  1). 
Multivariate logistic regression analysis showed that 
MELD and ALB were independent predictors of poor 
outcomes (p < 0.05).
Table 4 Severity and prognosis of DILI




 Liver diseases 22 70.97
 Other diseases 9 29.03
Died from anti-TB
 Drugs hepatoxity 10 32.26
 Hy’s cases 71 19.67
Mortality in Hy’s cases 9 2.68
Table 5 Logistic regression analysis
The bold italic data reflected significant difference
ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase, TBIL total bilirubin, DBIL bilirubin direct, PT thrombinogen time, INR international 
normalized ratio, TP total protein, ALB albumin, Cr Creatinine, MELD model for end-stage liver disease
Predictor Univariate analysis Multivariate analysis
95 % CI p value 95 % CI p value
Male 0.495–2.203 0.923
Female 0.454–2.019 0.923
Age (y) 0.996–1.045 0.110
Alcohol consumption 0.937–6.784 0.046 0.718–11.505 0.136
Pre-existing liver disease 0.935–4.46 0.073
Causative drugs
 Chinese herbal medicine 0.438–2.070 0.949
 Antithyroid 0.249–2.350 0.804
 Antituberculosis 1.732–8.819 0.001 0.270–82.810 0.288
 Antibiotics 0.137–3.173 0.879
 Chemotherapy drugs 0.166–3.918 0.986
 Antipyretics and analgesics 0.048–4.723 0.883
 Days from drug use to symptom appearance 0.999–1.000 0.992
 Days from drug discontinuation to symptom disappearance 0.984–1.024 0.268
 ALT (U/L) 1.000–1.000 0.425
 AST (U/L) 1.000–1.001 0.281
 ALP (U/L) 0.997–1.001 0.838
 TBIL (μmol/L) 1.002–1.006 <0.001 0.990–1.012 0.874
 DBIL (μmol/L) 1.001–1.006 0.013 0.982–1.011 0.602
 PT 1.053–1.155 <0.001 0.875–1.071 0.531
 INR 1.469–3.370 <0.001 0.713–2.600 0.350
 TP (g/L) 0.874–0.964 0.001 0.915–1.066 0.744
 ALB (g/L) 0.809–0.927 <0.001 0.772–0.983 0.025
 Cr (μmol/L) 0.997–1.004 0.369
 MELD 1.056–1.168 <0.001 1.004–1.192  0.041
Type of DILI
 Hepatocellular 0.375–1.671 0.539
 Cholestatic 0.791–4.792 0.147
 Mixed 0.322–2.885 0.527
 Hy’s case 0.197–1.719 0.327
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Discussion
Our statistical data indicated that the crude annual DILI 
incidence in hospitalized patients was 92.95/100,000. 
This is higher than the incidence rate reported in Ice-
land (19.1/100,000 inhabitants) (Björnsson et  al. 2013). 
Certainly, the study population is different and may be 
the reason for the difference, especially as the drug use 
in hospitalized patients may be higher. As there is a lack 
of epidemiological data for it, the DILI incidence in the 
general population of China is not known.
In hospitalized patients, misdiagnosis and missed diag-
nosis are common, and there is still no standard diag-
nostic criteria for DILI in China. Most of the diagnoses 
are based on the physicians’ individual ability and expe-
rience, and the RUCAM causality assessment is seldom 
used. Sometimes, because of conflicts with the hospital 
administration, physicians often refuse to diagnose DILI, 
which leads to a missed diagnosis. Therefore, there is a 
clear need to establish standard diagnostic criteria and 
reporting guidelines for DILI.
It is generally believed that the incidence of DILI is 
higher in patients aged over 50  years and that the inci-
dence of DILI increases with age (Björnsson et al. 2013; 
Chalasani et al. 2014). However, in our group of hospital-
ized patients, the incidence was the highest in the 41- to 
50-year age group. However, it should be noted that this 
does not reflect its incidence in the general population.
In China, Chinese herbal medicine is broadly accepted 
as safe and effective medication for the treatment of 
various ailments. The diagnosis and treatment strategies 
of traditional Chinese medicine are completely differ-
ent from those of Western medicine. In traditional Chi-
nese medicine, the practice is experienced-based rather 
than evidence-based. Therefore, very often, there is not 
enough evidence to prove the treatment and side effects 
of a drug. Our data suggest that the use of Chinese herbal 
medicine was associated with more than one-third of 
the DILI cases (36.01  %) in all the hospitalized patients 
diagnosed with DILI. In Korea and Singapore too, herbal 
medicine has been reported to be the leading cause of 
DILI (Suk et al. 2012; Wai 2006). Another group of data 
from Shanghai (China) also confirmed that Chinese 
herbal medicine accounted for 53.62 % of DILI cases in 
hospitalized patients diagnosed with DILI (Lai et  al. 
2012). Thus, it is important to monitor the hepatotoxicity 
of Chinese herbal medicine. This is especially important 
as the dosage of herbal drugs and their compositions vary 
between these traditional practitioners, and it is therefore 
very difficult to determine which component or, rather, 
components is the cause of the liver injury. Currently, 
only a few components of Chinese herbal medicine are 
known to cause DILI. There seems to be an urgent need 
to standardize the compositions of herbal medication 
and provide guidelines for the dosage.
The incidence of hyperthyroidism and tuberculosis 
is fairly high in China, which is reflected in our results: 
antithyroid and antituberculosis drugs were found to be 
the second and third most hepatotoxic drugs. Recently, 
a nationwide retrospective epidemiological investiga-
tion on DILI has been undertaken by a study group, with 
more than 300 hospitals participating; the results of this 
study will be highly useful for clarifying the DILI situa-
tion in the general population of China.
According to our data, the prognosis of most DILI 
patients was good, and the survival rate was 91.41  %. 
The manifestation was mild in most of the patients, and 
some patients were even asymptomatic. Further, the 
liver function of the patients rapidly improved after the 
Fig. 1 Logistic regression analysis. TBIL total bilirubin, DBIL direct bilirubin, TP total protein, ALB albumin, PT thrombinogen time, INR international 
normalized ratio, MELD model for end-stage liver disease, OR odds ratios, CI confidence intervals
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hepatotoxic drugs were discontinued. These findings sug-
gest that early detection of abnormal liver function and 
timely discontinuation of the drugs are very necessary. 
Generally, the mortality rate of DILI has been reported 
to be 8–17  % (Larrey and Pageaux 2005; Andrade et  al. 
2005; Chalasani et al. 2008; Devarbhavi et al. 2010). In our 
study, the mortality rate was 8.59  %. According to Hy’s 
law, if hepatocellular injury causes jaundice in a patient 
during a phase three trial, have at least a 10 % mortality 
rate (Temple 2006). In our investigation, the mortality 
rate in Hy’s cases was 12.69 %, these findings confirmed 
Hy’s theory is an important indicator of the potential of 
a drug to cause serious liver injury. This observation was 
also confirmed in some large studies on DILI in Spain 
(Andrade et  al. 2005) and in Sweden (Björnsson et  al. 
2005) in which 10 % of the subjects with hyperbilirubine-
mia or jaundice died or needed liver transplants.
The risk factors for mortality were baseline alcohol 
consumption, the use of antituberculosis drugs, TBIL, 
DBIL, PT, INR MELD score, TP and ALB. Among these 
risk factors, alcohol consumption was associated with 
poor outcome. However, there is not enough evidence to 
indicate that chronic alcohol consumption is a risk factor 
for all-cause DILI. It has been reported that heavy alcohol 
consumption is a risk factor for DILI owing to the pres-
ence of compounds such as APAP, methotrexate, and iso-
niazid (Chalasani et al. 2014).
The other risk factor for mortality is antituberculosis 
drugs, as it is well known that antituberculosis drugs such 
as rifampicin, isoniazid and pyrazinamide have strong 
hepatotoxicity. A study from India revealed acute liver 
failure occurred in a quarter of DILI patients receipted 
antituberculosis treatment and the overall motality was 
22.7  % (Devarbhavi et  al. 2013). Our data also indicate 
that antituberculosis drugs caused 32.26 % of the mortal-
ities, which suggested that the hepatoxicity of antituber-
culosis medication is a serious problem among patients 
undergoing antituberculosis treatment. A survey from 
Taiwan followed 926 patients for 4122.9 person-months 
(pm) and found that 111 (12.0 %) developed hepatotox-
icity after a median of 38.0 days from the start of treat-
ment; moreover, the severe hepatotoxicity rate was 3.5 %. 
The independent risk factors for hepatotoxicity were old 
age, female sex, autoimmune disease, human immuno-
deficiency virus infection, higher pyrazinamide dosage 
in the last 8–14 days, and lower rifampicin dosage in the 
last 15–21 days (Shu et al. 2013).
The other risk factors for mortality were TBIL, DBIL, 
TP, ALB, PT, INR and the MELD score, which reflect the 
state of the liver parenchyma. Compared to ALT, AST or 
ALP, these risk factors can more objectively and accu-
rately reflect the degree of damage to the liver paren-
chyma. Increase in TBIL, DBIL, PT, INR and the MELD 
score was accompanied by an increase in mortality; this 
is expected, as increase in these biochemical indices is 
one of the criteria for diagnosis of liver dysfunction. On 
the other hand, increase in the level of some indicators 
such as ALB was accompanied with a decrease in mortal-
ity. Our results also show that sex, age, latencies and DILI 
type are not correlated with DILI-associated mortal-
ity. This finding is consistent with studies from the USA 
(Chalasani et al. 2015) and Korea (Jeong et al. 2015). The 
data from the US study showed that the DILI-associated 
mortality was significantly higher in individuals with pre-
existing liver disease (Chalasani et  al. 2015). Although 
our results showed that pre-existing disease is not a risk 
factor for DILI-associated mortality (p  =  0.073), the 
results did indicate that pre-existing liver disease could 
enhance the mortality. This needs to be examined in a 
larger population in order to confirm the results.
Our study found that the MELD score and ALB were 
independently associated with poor outcome. Thus, the 
MELD score and ALB are key risk factors for DILI-asso-
ciated mortality. The MELD score is widely accepted as 
an accurate predictor of mortality across a broad spec-
trum of liver diseases (Said et al. 2004; Martin et al. 2014). 
The study from Korea also confirmed that the c-statistic 
for the MELD score alone was 0.93 and that the MELD 
score had strong discriminatory power and may be a 
reliable predictor of the prognosis in patients with DILI 
(Jeong et al. 2015).
One of the main limitations of our study is its nature, 
this study being a single-center retrospective study. 
Another limitation was that some important examina-
tions such as liver biopsy were not performed in most of 
the patients, and the data for some important biochemi-
cal indexes were missing from the first time the patients 
were diagnosed with DILI. Moreover, we did not con-
sider the effects of drug interaction in cases where mul-
tiple drugs were used, as these interactions are quite 
complicated and unclear. In China, several drugs for 
liver protection are used in cases of DILI, usually at least 
two different liver protection drugs for one patient. This 
makes it difficult to compare the therapeutic effects of 
these drugs, so we did not analyze the treatment data in 
our study.
In summary, Chinese herbal medicine was the main 
cause of DILI in hospitalized patients in China, followed 
by antithyroid and antituberculosis drugs. The survival 
rate was 91.41 %. The major cause of mortality was severe 
liver diseases, and primary diseases were the other cause. 
DILI associated with the use of antituberculosis drugs 
was the cause in 32.26 % of the patients. Further, alcohol 
consumption, the use of antituberculosis drugs, serum 
TBIL, DBIL, TP, ALB, PT, INR and the MELD score were 
significantly correlated with DILI-associated mortality. 
Page 8 of 8Ou et al. SpringerPlus  (2015) 4:802 
Among them, the MELD score and ALB were independ-
ent predictors of outcome in patients with DILI.
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